Australian clinical-stage biotechnology company Vaxxas has expanded its global intellectual property portfolio to 42 patents, supporting its exclusive claim to manufacture and sell its proprietary vaccination technology, the HD-MAP, in the US, Europe, Asia and Australia. …
Vaxxas expands global IP portfolio for exclusive manufacture and sale of needle-free vaccination technology
November 27, 2024 Australian Biotech
Latest Video
New Stories
-
Access delayed - the stakes are high for the industry's next agreements
October 27, 2026 - - Latest News -
Services Australia annual report confirms decline in prescription volume
October 27, 2026 - - Latest News -
CSL announces new chair as Brian McNamee prepares to bow out
October 26, 2026 - - Latest News -
There is an urgent need to reconsider the question of PBS sustainability
October 26, 2026 - - Latest News -
PBS share of health spending on track to halve as Canberra prepares to negotiate with industry
October 26, 2026 - - Latest News -
Documents reveal net PBS spending set to remain on life support to the end of decade
October 26, 2026 - - Latest News -
Health's multi-million dollar rebuild of cost-recovery fees is happening out of view
October 26, 2026 - - Latest News